YOLFTbeta
Chimeric Therapeutics Ltd

Chimeric Therapeutics Ltd

CHM · AU · Healthcare / Biotechnology

0.003AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.003
Open0.003
Day Range0.003 – 0.003
52-Week Range0.003 – 0.40
Volume0
Market Cap442.38K
P/E (TTM)0.00
Forward P/E0.00
EPS-0.61
Dividend Yield0.00%
Beta0.64
50-Day Avg0.0191
200-Day Avg0.1228

About

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Rebecca McQualter
  • Employees0
  • Headquarters62 Lygon Street, Carlton, VIC, Australia, 3053, Australia
  • Websitehttps://www.chimerictherapeutics.com

Leadership

  • Dr. Rebecca McQualterChief Executive Officer
  • Mr. Aaron LauritaChief Financial Officer
  • Dr. Stephanie H. Astrow MBA, Ph.D.Chief Scientific Officer · b. 1962
  • Dr. Agathe BourgogneHead of Manufacturing
  • Mr. Nathan Jong C.A.Joint Company Secretary

Financials

Income Statement

Currency: AUD2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue02.65K2.62M4.51M7.46M3.97M-
Growth (%)--+98808.62%+72.16%+65.52%-46.79%-
Cost of Revenue-846.96K949.76K965.35K3.92K846.76K-
Gross Profit--844.31K1.67M3.54M7.45M3.12M-
Gross Margin--31909.07%63.71%78.58%99.95%78.66%-
Operating Expense-14.00M16.24M33.03M19.76M18.23M-
Operating Income-64.01K-14.85M-14.57M-29.49M-12.31M-15.11M-8.36M
Operating Margin--561099.40%-556.82%-654.44%-165.06%-380.78%-
EBITDA-64.01K-14.26M-13.62M-28.59M-11.30M-9.08M-8.36M
EBITDA Margin--538959.71%-520.53%-634.54%-151.52%-228.71%-
Net Income-64.01K-15.11M-15.90M-25.92M-12.53M-10.43M-18.81M
Net Income Margin--571190.89%-607.48%-575.20%-168.01%-262.83%-
R&D-3.78M5.17M13.47M10.15M9.76M3.42M
R&D as % of Total Revenue-142795.99%197.70%299.06%136.05%245.98%-
Interest Expense05.88K640.13K773.85K331.81K211.03K-
Interest Expense % of Total Revenue-222.11%24.46%17.17%4.45%5.32%-

Balance Sheet

Currency: AUD2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets10036.50M34.88M22.38M15.27M21.57M1.28M
Total Liabilities64.01K11.37M9.17M16.71M12.80M19.60M9.00M
Total Equity-63.91K25.13M25.71M5.66M2.47M1.97M-7.72M
Cash10022.41M18.38M5.37M3.05M5.76M800.14K
Total Debt34.01K3.68M--3.59M-679.85K
Net Debt33.91K-22.41M-18.38M-5.37M-3.05M-5.76M-120.30K

Cash Flow

Currency: AUD2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-34.01K-8.84M-13.15M-16.32M-7.54M-7.28M-10.78M
Investing Cash Flow-5.31M-5.30M-577.86K-112.19K---249.34K
Financing Cash Flow34.11K36.54M9.50M253.38K8.26M10.05M6.08M
Capital Expenditure16.26K5.31M537.86K112.19K7.55M110.78M
Free Cash Flow-34.01K-14.15M-13.69M-16.43M10.11K-7.28M-
Dividends Paid--4.05M2.31M---
FCF to OCF100.00%160.02%104.09%100.69%-0.13%100.00%-
Dividend Paid to FCF---29.56%-14.08%---

Earnings

Report DateFeb 26, 2021Aug 30, 2021Feb 27, 2022Sep 30, 2022Feb 28, 2023Feb 28, 2025Aug 29, 2025
EPS Estimate0.00-0.000.00-0.000.00
EPS Actual-0.06-0.04-0.03-0.01-0.030.000.00
Surprise-------
TimingAfter-hoursAfter-hoursAfter-hoursPre-marketPre-market--

Key Statistics & Ratios

Market Cap442.38K
Enterprise Value352.21K
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.07
Price / Book4.94
EPS-0.61
Book Value-0.141
Revenue (TTM)-189.84K
Gross Profit (TTM)-189.84K
EBITDA-8.03M
Profit Margin0.00%
Operating Margin258.99%
Return on Equity-1290.99%
Return on Assets-46.75%
Shares Outstanding147.46M
Shares Float45.82M
Beta0.64
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Apr 22, 20261:100